Colleen Badgley

Full contact info

About Colleen

Colleen represents emerging high-growth companies throughout their life cycle, with a focus on all aspects of emerging company development – including corporate formation, venture capital financings, corporate spinouts and restructurings, mergers & acquisitions, and capital markets transactions. She also has experience representing venture capital and angel investors in their investment transactions. Since 2021, Colleen has handled VC financings with an aggregate deal value of more than $1 billion. Colleen is counsel to companies and their investors in a broad range of industries on a global basis, with a focus on the biotechnology, medical device, digital health and software sectors.

Colleen’s private company clients have included Archon Biosciences, Artemis Health (acquired by Nomi Health), Arzeda, Bonum Therapeutics, Donuts (acquired by Abry Partners), Good Therapeutics (acquired by Roche), ISHI Health, LiveStories (doing business as FORWARD), Lumen Bioscience, Myosana Therapeutics, Nest Healthcare, New Engen (acquired by Insignia Capital), Parse Biosciences, Petra Pharma, Polyarc, PvP Biologics (acquired by Takeda Pharmaceuticals), Syndio, Talking Rain, Tasso and Vilya. Her public company clients have included Accolade, Alder BioPharmaceuticals (acquired by Lundbeck), Bolt Biotherapeutics, Etsy, Instacart and Instructure (acquired by Thoma Bravo). VC firms and investment banks Colleen has represented include Barclays Capital, Cowen and Company, Decheng Capital, Founders’ Co-op, General Catalyst, Goldman Sachs, Jefferies, Lobby Capital, Madrona Venture Group, Redpoint Ventures, and Vulcan Capital.

Colleen’s recent representative transactions include advising:

  • Accolade in its $221 million secondary public offering
  • Bolt Biotherapeutics in its $264 million initial public offering
  • Bonum Therapeutics in its spinout from Good Therapeutics and its $93 million Series A financing
  • Form Bio in its $30 million Series A financing
  • Good Therapeutics in its sale to Roche for $250 million upfront
  • Kimia Therapeutics in its spinout from Carmot Therapeutics
  • Parse Biosciences in its $50 million Series C equity and debt financing
  • Petra Pharma in its sale to Eli Lilly for an undisclosed amount
  • Polyarc in its $9 million Series B financing
  • Syndio in its $17 million Series B financing
  • Uplevel in its $20 million Series A financing
  • Vilya in its $50 million Series A financing

While attending the University of Michigan Law School, Colleen served as an international fellow at the World Intellectual Property Organization in Geneva, Switzerland, and was a member of the Zell Entrepreneurship Clinic.




University of Michigan Law School
JD, 2014, magna cum laude

Loyola Marymount University
BA, 2011, Psychology, magna cum laude